Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

NEXT STORY
Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020
PREV STORY
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer

AMES, Iowa, Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced ...

author_avatar
NASDAQ Market News

Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206

CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset ...

author_avatar
NASDAQ Market News

Loxo Oncology to Present at the JMP Securities Life Sciences Conference

STAMFORD, Conn., June 14, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

author_avatar
NASDAQ Market News